+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Papillomavirus Testing Market by Test Type, Technology, End User, Indication - Global Forecast to 2030- Product Image
Human Papillomavirus Testing Market by Test Type, Technology, End User, Indication - Global Forecast to 2030- Product Image
Sale

Human Papillomavirus Testing Market by Test Type, Technology, End User, Indication - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904933
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Papillomavirus Testing Market grew from USD 1.26 billion in 2024 to USD 1.44 billion in 2025. It is expected to continue growing at a CAGR of 13.62%, reaching USD 2.72 billion by 2030.

Setting the Stage for HPV Testing Evolution

The landscape of human papillomavirus testing has evolved into a high-priority frontier for public health decision-makers, diagnostics developers, and healthcare providers globally. Rising awareness of HPV’s link to cervical and other cancers has intensified demand for accurate, cost-effective screening solutions. In parallel, regulatory agencies are streamlining approval pathways, spurring the launch of novel assays and instrumentation that promise to enhance early detection and patient compliance.

Technological breakthroughs are reshaping traditional paradigms: molecular platforms once confined to central laboratories are now trending towards point-of-care formats, while liquid-based cytology continues to refine morphological analysis with automated image recognition. As these innovations converge with digital health initiatives, the industry stands at a transformative threshold.

This report delivers a strategically structured overview of market shifts, tariff impacts, segmentation nuances, regional disparities, and competitive intelligence. By weaving empirical data with expert perspectives, it equips stakeholders with the knowledge required to navigate complexities and capitalize on emerging growth avenues.

Disruptive Forces Redefining HPV Testing Paradigms

The HPV testing landscape is undergoing paradigm shifts driven by advances in assay chemistry, data analytics, and patient convenience. Molecular diagnostics are redefining screening standards as PCR-enabled tests achieve higher sensitivity and specificity compared to traditional cytology. Simultaneously, next-generation sequencing has emerged as a powerful tool for comprehensive genotype profiling, enabling risk stratification and personalized follow-up protocols.

At the same time, liquid-based cytology has gained traction for its ability to integrate morphological assessment with adjunct molecular testing, while self-administered rapid tests are expanding access in underserved communities. These developments reflect a broader trend towards decentralization, with point-of-care devices offering near-immediate results and streamlined workflows.

Moreover, digital connectivity is transforming laboratory operations through cloud-based data aggregation and AI-driven interpretation, reducing manual workloads and enhancing diagnostic accuracy. These intertwined forces are not only elevating clinical performance metrics but also reshaping market entry strategies for device manufacturers and assay developers alike.

Assessing the Tariff Ripple Effects on the US HPV Testing Market

The introduction of new tariffs on imported diagnostic reagents and instrumentation in 2025 has reverberated across the U.S. HPV testing market. Costs for PCR reagents, next-generation sequencing consumables, and automated cytology platforms have risen, prompting laboratories and healthcare providers to reevaluate procurement strategies. Margins have come under pressure as distributors negotiate pass-through price adjustments to maintain service levels without compromising quality.

This regulatory shift has accelerated a pivot towards domestic manufacturing and localized supply chains, with some stakeholders forging partnerships to secure raw materials and mitigate volatility. Manufacturers have also explored dual sourcing of critical components and increased inventory buffers to safeguard against potential disruptions.

While short-term cost increases are palpable, these measures may bolster long-term resilience. The increased emphasis on domestic capacity could spur innovation in reagent formulation and assay design, ultimately driving greater supply stability and competitive differentiation in the HPV testing landscape.

Deep Dive into Crucial HPV Testing Segmentation

A nuanced understanding of market segmentation is fundamental for strategic decision-making. When evaluating test offerings, it is crucial to consider that the market divides into cytology tests, molecular assays, and rapid platforms. Within cytology, both conventional slide methods and liquid-based techniques cater to distinct laboratory workflows and sample preservation needs. Molecular assays bifurcate into PCR enabled methods and sequencing enabled technologies, with PCR tests further distinguished by digital PCR and real-time PCR modalities, while sequencing tests split between next-generation and Sanger platforms. Rapid tests, meanwhile, span point-of-care devices for on-the-spot screening and self-administered kits designed for at-home use.

Technology-centric segmentation highlights the roles of hybrid capture assays alongside PCR and sequencing approaches, each delivering varying levels of throughput, sensitivity, and multiplexing capability. The user environment also shapes demand: primary care and specialty clinics, private and public hospitals, and both hospital-based and independent laboratories require tailored solutions that align with operational workflows and volume requirements.

Finally, clinical indications influence uptake: co-testing protocols differentiate between high-risk and routine screenings, primary screening approaches segment by age cohorts-specifically those aged 21 to 29 versus 30 and above-and reflex testing categorizes cases into ASC-US and LSIL follow-ups. Recognizing these interwoven layers of segmentation empowers stakeholders to target offerings precisely and maximize adoption rates.

Regional Variations Shaping the Global HPV Testing Market

Regional dynamics exert a powerful influence on market performance and strategic priorities. In the Americas, established screening programs and favorable reimbursement environments underpin a mature market with steady demand for advanced diagnostics. Healthcare providers in this region often lead in adopting next-generation sequencing and digital PCR to refine risk assessment and patient management.

Across Europe, Middle East & Africa, a diverse mix of regulatory frameworks and economic conditions shapes adoption rates. Western European markets drive growth through harmonized guidelines and high public awareness, while emerging economies in the Middle East and Africa pursue capacity building in laboratory infrastructure and workforce training to expand access.

In the Asia-Pacific arena, rapid urbanization and expanding private healthcare networks are catalyzing investment in cutting-edge platforms. Government initiatives focused on cervical cancer screening and public health education are further stimulating demand. Market entrants in this region often prioritize scalable molecular assays and cost-effective point-of-care solutions to address heterogeneous patient populations and infrastructure constraints.

Competitive Landscape and Leading Players in HPV Diagnostics

The competitive terrain in HPV diagnostics is defined by established players and agile innovators alike. Industry leaders have fortified positions through diversified assay portfolios spanning hybrid capture, PCR methodologies, and next-generation sequencing, ensuring comprehensive solutions for varying laboratory setups. Strategic alliances and licensing agreements have accelerated time-to-market for novel tests, while acquisitions have bolstered vertical integration across reagent supply and instrument manufacturing.

Emerging companies are carving niches by focusing on rapid, point-of-care platforms that emphasize portability and minimal operational complexity. Some have differentiated through proprietary chemistries that enhance multiplexing capabilities or reduce sample preparation steps, appealing to decentralized screening initiatives. Concurrently, digital health startups are integrating AI-driven analytics into their offerings, creating end-to-end ecosystems that link diagnostic outputs with risk stratification software and telehealth services.

This blend of legacy expertise and disruptive innovation fosters a dynamic environment where product pipelines, regulatory approvals, and go-to-market strategies continually evolve. Companies that align technological advancements with robust commercialization frameworks are set to outpace competitors and capture incremental market share.

Strategic Imperatives for Accelerating Market Growth

For organizations seeking to capitalize on HPV testing growth, a set of strategic imperatives has emerged. First, investing in modular assay platforms that accommodate both PCR and sequencing workflows can create cross-selling opportunities and optimize instrument utilization. Second, diversifying reagent sourcing through dual-supply agreements and regional manufacturing partnerships will mitigate tariff-related risks and enhance supply security.

Third, expanding self-administered and point-of-care offerings can drive penetration in underserved markets, leveraging consumer convenience and reducing clinic burden. Fourth, forging alliances with telehealth providers to integrate diagnostic data into patient management systems will unlock value by enabling remote follow-up and population-level analytics.

Finally, prioritizing emerging markets in Asia-Pacific and EMEA through tiered pricing and localized support structures will amplify adoption. By aligning product roadmaps with regional screening guidelines and payer requirements, industry leaders can accelerate growth while reinforcing their reputations as reliable partners in global health.

Robust Methodological Framework Underpinning the Analysis

This analysis is grounded in a rigorous methodological framework that synthesizes primary and secondary research streams. In-depth interviews with clinical laboratory directors, regulatory authorities, and key technology vendors were conducted to capture real-world operational insights and emerging priorities. Secondary data sources-including peer-reviewed literature, clinical trial registries, and government publications-provided quantitative validation and trend context.

Data triangulation techniques reconciled variations across sources, ensuring robust and consistent findings. A comprehensive review of regulatory filings, patent landscapes, and reimbursement policies further illuminated market entry barriers and enablers. Forecasting scenarios, while not disclosed here, were developed using proprietary models calibrated against historical uptake curves and technology adoption benchmarks.

Throughout the process, quality control measures-such as peer reviews and data audits-were implemented to maintain objectivity and accuracy. This methodological rigor underpins every insight presented, offering stakeholders a reliable foundation for strategic planning and investment decisions.

Consolidating Insights for Strategic Decision-Making

The insights consolidated within this executive summary underscore the multifaceted nature of the human papillomavirus testing market. Technological innovation is driving a shift from conventional cytology towards molecular and rapid testing formats, while regulatory and tariff dynamics are reshaping supply chains and pricing strategies. Deep segmentation analysis reveals that successful market penetration hinges on aligning product offerings with specific test types, technologies, end-user needs, and clinical indications.

Regional landscapes-from the mature diagnostics environment in the Americas to the rapidly expanding Asia-Pacific and the diverse regulatory terrain of Europe, Middle East & Africa-demand tailored approaches. Competitive analysis highlights that both entrenched corporations and nimble disruptors play vital roles in defining market trajectories.

As organizations chart their next moves, integrating these insights into strategic roadmaps will be critical. Whether refining R&D pipelines, optimizing operations, or expanding market access, the ability to interpret and act on this intricate mosaic of factors will determine long-term success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Cytology Tests
      • Conventional
      • Liquid Based
    • Molecular Tests
      • Pcr Enabled
      • Sequencing Enabled
    • Rapid Tests
      • Point Of Care
      • Self Administered
  • Technology
    • Hybrid Capture
    • Pcr
      • Digital
      • Real Time
    • Sequencing
      • Next Generation
      • Sanger
  • End User
    • Clinics
      • Primary Care
      • Specialist
    • Hospitals
      • Private
      • Public
    • Laboratories
      • Hospital Based
      • Independent
  • Indication
    • Co Testing
      • High Risk
      • Routine
    • Primary Screening
      • Age 21 To 29
      • Age 30 And Above
    • Reflex Testing
      • Asc Us
      • Lsil
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Roche Diagnostics International AG
  • Hologic, Inc.
  • QIAGEN N.V.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • PerkinElmer, Inc.
  • Siemens Healthineers AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Papillomavirus Testing Market, by Test Type
8.1. Introduction
8.2. Cytology Tests
8.2.1. Conventional
8.2.2. Liquid Based
8.3. Molecular Tests
8.3.1. Pcr Enabled
8.3.2. Sequencing Enabled
8.4. Rapid Tests
8.4.1. Point of Care
8.4.2. Self Administered
9. Human Papillomavirus Testing Market, by Technology
9.1. Introduction
9.2. Hybrid Capture
9.3. Pcr
9.3.1. Digital
9.3.2. Real Time
9.4. Sequencing
9.4.1. Next Generation
9.4.2. Sanger
10. Human Papillomavirus Testing Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Primary Care
10.2.2. Specialist
10.3. Hospitals
10.3.1. Private
10.3.2. Public
10.4. Laboratories
10.4.1. Hospital Based
10.4.2. Independent
11. Human Papillomavirus Testing Market, by Indication
11.1. Introduction
11.2. Co Testing
11.2.1. High Risk
11.2.2. Routine
11.3. Primary Screening
11.3.1. Age 21 to 29
11.3.2. Age 30 and Above
11.4. Reflex Testing
11.4.1. Asc Us
11.4.2. Lsil
12. Americas Human Papillomavirus Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Human Papillomavirus Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Human Papillomavirus Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Diagnostics International AG
15.3.2. Hologic, Inc.
15.3.3. QIAGEN N.V.
15.3.4. Abbott Laboratories
15.3.5. Becton, Dickinson and Company
15.3.6. Danaher Corporation
15.3.7. Thermo Fisher Scientific Inc.
15.3.8. bioMérieux SA
15.3.9. PerkinElmer, Inc.
15.3.10. Siemens Healthineers AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET MULTI-CURRENCY
FIGURE 2. HUMAN PAPILLOMAVIRUS TESTING MARKET MULTI-LANGUAGE
FIGURE 3. HUMAN PAPILLOMAVIRUS TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 89. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 90. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 91. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 93. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 94. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 96. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 97. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 98. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 100. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 101. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 102. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 108. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 109. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 115. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 116. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 178. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 184. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 185. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 189. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 191. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 192. GERMANY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 193. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 194. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 195. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 196. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 199. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 200. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 204. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 206. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 207. FRANCE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 223. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 224. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 225. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 226. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 227. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 228. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 229. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 230. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 232. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 234. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 236. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 237. ITALY HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 238. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 239. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 240. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 241. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 242. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 244. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 245. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 249. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 251. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 252. SPAIN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 298. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 299. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 300. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 302. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 303. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 304. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 305. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 307. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 308. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 309. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2030 (USD MILLION)
TABLE 311. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2030 (USD MILLION)
TABLE 312. DENMARK HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2030 (USD MILLION)
TABLE 313. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 314. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2030 (USD MILLION)
TABLE 315. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 316. NETHERLANDS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2030 (USD MILLION)
TABLE 317. NETHERLANDS HUMAN PAPILLOMAVIRUS TE

Companies Mentioned

The companies profiled in this Human Papillomavirus Testing market report include:
  • Roche Diagnostics International AG
  • Hologic, Inc.
  • QIAGEN N.V.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • PerkinElmer, Inc.
  • Siemens Healthineers AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.72 Billion
Compound Annual Growth Rate13.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

2024-2029 Global Papillomavirus Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities - Product Image

2024-2029 Global Papillomavirus Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

  • Report
  • Europe, Global, Japan, ... Europe, Global, Japan, United States
From
Human Papillomavirus (HPV) Testing - Global Strategic Business Report - Product Image

Human Papillomavirus (HPV) Testing - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
STD Testing - Global Strategic Business Report - Product Image

STD Testing - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Sexually Transmitted Diseases Diagnostics Market by Technology, Disease, End User, Distribution Channel, Test Type, Sample Type - Global Forecast to 2030 - Product Image

Sexually Transmitted Diseases Diagnostics Market by Technology, Disease, End User, Distribution Channel, Test Type, Sample Type - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From

About the HPV Test Market

The HPV Test is a type of infectious disease testing used to detect the presence of Human Papillomavirus (HPV). HPV is a sexually transmitted virus that can cause cervical cancer and other types of cancer. The HPV Test is used to detect the presence of the virus in the body and can be used to diagnose HPV-related diseases. The test is typically performed by collecting a sample of cells from the cervix and testing them for the presence of HPV. The HPV Test market is a growing segment of the infectious disease testing industry. The test is used by healthcare providers to diagnose and monitor HPV-related diseases, as well as to screen for the virus in individuals who may be at risk. The market is expected to continue to grow as more healthcare providers adopt the test and as awareness of HPV-related diseases increases. Some companies in the HPV Test market include Roche Diagnostics, Abbott Laboratories, Becton Dickinson, and Cepheid. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.